Skip to content

AbbVie ABBV Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

The Beauty Health Company logo
The Beauty Health CompanySKIN

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$453.91B+36.3%
P/E124.9×+36.4×
P/S7.2×+1.5×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's amortization of capitalized software and acquired intangible assets?
AbbVie (ABBV) reported amortization of capitalized software and acquired intangible assets of $1.75B in Q1 2026.
How has AbbVie's amortization of capitalized software and acquired intangible assets changed year-over-year?
AbbVie's amortization of capitalized software and acquired intangible assets decreased by 5.9% year-over-year, from $1.86B to $1.75B.
What is the long-term trend for AbbVie's amortization of capitalized software and acquired intangible assets?
Over 4 years (2021 to 2025), AbbVie's amortization of capitalized software and acquired intangible assets has grown at a -0.9% compound annual growth rate (CAGR), from $7.72B to $7.44B.